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Summary
A specific association with mixed lineage leukemias suggests that MLL oncoproteins may selectively target early multipotent
hematopoietic progenitors or stem cells. We demonstrate here that a representative MLL fusion protein, MLL-GAS7, impairs
the differentiation and enhances the in vitro growth of murine hematopoietic cells with multipotent features. The multilineage
differentiation potential of these cells was suggested by their immuno-phenotypes and transcriptional programs and
confirmed by their ability to induce three pathologically distinct leukemias in mice, including an acute biphenotypic leukemia
(ABL) that recapitulates the distinctive hallmark features of many MLL-associated leukemias in humans. This experimental
modeling of ABL in mice highlights its origin from multipotential progenitors that arrest at a bipotential stage specifically
targeted or induced by MLL oncogenes.
Introduction MLL oncoproteins may transform early progenitors of either
the myeloid or lymphoid lineages, but leukemias with unusual
Chromosomal rearrangements of the Mixed Lineage Leukemia biphenotypic (ABL) features may result from so-called “lineage
(MLL) gene are associated with a subset of de novo and second- infidelity” representing aberrant expression of lineage-associ-
ary acute leukemias of both children and adults (Djabali et al., ated genes (McCulloch, 1983). Alternatively, MLL oncoproteins
1992; Gu et al., 1992; Tkachuk et al., 1992). As a consequence, may target hematopoietic cells with multilineage differentiation
MLL undergoes fusions with a wide variety of partner genes to potential, such as hematopoietic stem cells (HSC) (Morrison
yield a plethora of chimeric proteins in leukemias of either my- and Weissman, 1994), their immediate downstream progeny,
eloid or lymphoid derivation (Ayton and Cleary, 2001 for review). the multipotent progenitor (MPP) (Morrison et al., 1997), or pro-
The remarkable variety of MLL fusion partners (up to 50) and genitors with bilineage potential (Cumano et al., 1992; Mon-
tecino-Rodriguez et al., 2001). In this scenario, ABL may reca-their diverse lineage associations contrast with most other chi-
meric leukemia oncoproteins, which are not as variable and tend pitulate otherwise normal phenotypes of early progenitors
expressing dual lineage markers, a phenomenon called “lineageto be specific for leukemias of a single lineage. Furthermore, a
hallmark feature of many MLL-associated leukemias is the co- promiscuity” (Greaves et al., 1986). Elucidation of their origin
will further an understanding of the unique biology and etiologyexpression of both myeloid and lymphoid antigens representa-
tive of a biphenotypic or mixed lineage derivation (Chen et al., of mixed lineage leukemias, which are generally associated with
a poor clinical prognosis (Chen et al., 1993; Pui et al., 2002).1993), hence the name MLL (McCabe et al., 1992). In addition
to their unique phenotypes, MLL biphenotypic leukemias also Several animal models have been employed to study the
biological roles of MLL oncoproteins in leukemogenesis.display transcriptional programs distinct from those displayed
by myeloid or lymphoid acute leukemias, respectively (Arm- Knockin of AF9 into the Mll locus by homologous recombination
resulted in acute leukemias preceded by myeloproliferation thatstrong et al., 2002; Yeoh et al., 2002).
Two alternative, but not mutually exclusive, mechanisms mimics the corresponding human disease (Corral et al., 1996;
Dobson et al., 1999). Similarly, retroviral transduction/trans-have been proposed to account for mixed lineage features.
S I G N I F I C A N C E
A hallmark feature of many human leukemias that harbor mutations of the MLL oncogene is the co-expression of myeloid and
lymphoid antigens representative of a biphenotypic or mixed lineage derivation. We demonstrate that transduction of hematopoietic
cells with features of multipotent progenitors by an MLL oncogene resulted in multilineage leukemias, including acute myeloid,
lymphoid, and biphenotypic leukemias, that closely recapitulate the corresponding human diseases. By prospectively isolating and
transducing highly purified populations of hematopoietic stem cells and progenitors, we further demonstrate that stem cells, but not
myeloid or lymphoid committed progenitors, yield multilineage oncogenic readouts. These studies suggest that the unusual pathologic
and clinical features of MLL-associated leukemias result in part from selective oncogenic effects of MLL on multipotent progenitors,
consistent with a “lineage promiscuity” model for the pathogenesis of mixed lineage leukemias.
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yielded leukemias with myeloid/lymphoid biphenotypic fea-
tures. It is therefore still largely unknown how MLL oncoproteins
result in multilineage leukemias in humans.
We report here that a representative MLL fusion protein
(MLL-GAS7) impairs the differentiation and enhances the in vitro
growth of murine hematopoietic cells with features of MPP.
Transformed MPP-like cells induced leukemias of multiple lin-
eages in syngeneic mice including an acute biphenotypic leuke-
mia (ABL) expressing both myeloid and lymphoid antigens and
genes. Biphenotypic progenitors were also generated in vitro
from HSC transduced with MLL-GAS7. This represents a suc-
cessful modeling of ABL in mice and highlights its origin from
a previously undefined biphenotypic progenitor that may be
specifically affected by MLL oncogenes.
Results
Induction of mixed lineage leukemias by MLL-GAS7
Primary murine hematopoietic cells enriched for HSC and early
progenitors (c-kit fraction) were transduced with recombinant
retroviruses encoding MLL-GAS7 and then directly transplanted
into lethally irradiated, syngeneic mice (Figure 1A). All mice suc-
cumbed to leukemias within 5 months (Figure 1B). The leuke-
mias were oligoclonal as judged by proviral integration status
(Figure 1C), suggesting that MLL-GAS7 required few additional
mutations to induce leukemia in mice. Most (80%) of the leuke-
mias were AMLs based on phenotypic (c-kit/Mac1/Gr-1/
CD19/B220) and cytologic features. One was ALL as evi-
denced by its immunophenotype (c-kit/CD19/B220/Mac1/
Gr-1) and presence of Ig heavy chain gene rearrangements
(Figure 1C and data not shown). Notably, one of the leukemias
appeared to be of mixed lineage containing a subset of cells in
the bone marrow that displayed bilineage (c-kit/B220/Mac-
1/CD19/Gr-1) features (Figure 1C), as well as cells express-
ing exclusively myeloid antigens. At several extramedullary sites
of this mouse, only monoclonal myeloid leukemic cells were
present, suggesting that multiclonal leukemias arose in the bone
marrow from which individual leukemic clones disseminated to
peripheral sites (Figure 1C). These observations suggested that
MLL-GAS7 is directly capable of inducing leukemias of different
Figure 1. Induction of multilineage leukemias by MLL-GAS7 lineages in vivo, consistent with the early immature and lineage
A: Flow chart depicting the experimental approaches for in vitro and in promiscuous features of human leukemias associated with MLL
vivo transformation assays employed.
mutations.B: Survival curves are shown for cohorts (n  10) of lethally irradiated mice
transplanted with c-kit bone marrow cells transduced with MLL-GAS7 or
vector control.
MLL-GAS7 enhances the growth of hematopoietic cellsC: Development of multilineage leukemias in transplanted mice. FACS pro-
files show typical phenotypes of myeloid (AML) and lymphoid (ALL) leuke- with features of multipotent progenitors
mias (left panels). Panels on the right show features of leukemic subclones In vitro studies were conducted to investigate the possible onco-
that arose in the bone marrow, lymph node, and thymus of a single mouse
genic effects of MLL-GAS7 in hematopoietic cells with multilin-with leukemia of several different lineages and clonality. Lower panels show
eage differentiation potential. Primary murine hematopoieticthe immunoglobulin gene (IG-JH4) and MSCV retroviral integration (Proviral
insertion) status of leukemic cells as detected by Southern blot analysis. gl, stem cells and progenitors (from 5-FU treated BM) were trans-
germline configuration of IG-JH4 gene. duced with recombinant retroviruses encoding MLL-GAS7, or
the respective portions of MLL (5-MLL) or GAS7 (GAS7) (Fig-
ures 1A and 2A). Plating of transduced cells in methylcellulose
yielded similar numbers of G418-resistant colonies for each ofplantation assays have also successfully modeled the transfor-
the constructs, indicating comparable transduction efficiencies.mation properties of various MLL fusion proteins (Lavau et al.,
Cells transduced with MLL-GAS7 showed enhanced growth1997, 2000; Luo et al., 2001; DiMartino et al., 2002, So and
potential as evidenced by continued ability to generate com-Cleary, 2002, 2003). However, both experimental approaches
are highly biased toward myeloid leukemias, and none has pact, immature CFU-blast colonies upon serial replating in
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Figure 2. Cells transformed in vitro by MLL-GAS7
display phenotypic features of multipotential
progenitors
A: Schematic diagram of constructs used in he-
matopoietic progenitor transformation assays
(left). Bar graph (right) shows numbers of colonies
obtained after each round of plating in methyl-
cellulose (average of three independent assays)
following transduction of BM cells enriched for
stem/progenitor cells following 5-FU treatment.
Similar results were obtained with c-kit enriched
BM cells. Insert shows the typical morphology of
colonies generated in methylcellulose by bone
marrow cells transduced with MLL-GAS7.
B: Phenotypic analysis of cells transformed by
MLL-GAS7 in vitro. Shadow profiles represent
FACS staining obtained with antibodies specific
for the indicated cell surface antigens. Red lines
represent staining obtained with isotype control
antibodies.
methylcellulose culture (Figure 2A). Cells harvested from second and phenotypic features (Table 1 and Figure 3C) that defined
three specific subtypes. These were: (1) AML with features ofor third round methylcellulose cultures (200–400 pooled colo-
early myeloid precursors (c-kit/Mac-1/Gr-1/B220/CD19);nies) gave rise to long-term growth of clonal populations in
(2) ALL with features of early B-lymphoid precursors (c-kit/liquid medium. Interestingly, their immunophenotypes showed
CD43/B220/BP-1/CD19/Mac-1/Gr-1); and (3) acute bi-high level co-expression of c-kit and Sca-1 (Figure 2B), a charac-
phenotypic leukemia (ABL) comprised of blasts co-expressingteristic phenotype of HSC and MPP (Morrison and Weissman,
both myeloid and lymphoid markers (c-kit/Mac-1/B220/1994; Morrison et al., 1997). They were negative for most lin-
CD19/Gr-1). The leukemia subtypes were similar to thoseeage-specific markers tested (Gr-1, CD19, Ter119, CD8) except
resulting from the direct transplant experiments (Figure 1) indi-B220lo and Mac-1, which also can be expressed by MPP (Mor-
cating that this was a reproducible feature of MLL-GAS7-rison et al., 1997). These data suggested that MLL-GAS7 en-
induced leukemias. Although the leukemic cells from all threehanced the in vitro growth of cells with some features of MPP.
subtypes lacked expression of Sca-1, which distinguished themWe will therefore refer to them as MPP-like based on their
from the injected MPP-like cells, all subtypes displayed identicalphenotypic and functional (defined below) properties.
genomic configurations of the integrated MSCV/MLL-GAS7
provirus on Southern blot analysis (Figure 3C), indicating that
Transformed MPP-like cells induce leukemias they derived from a single clone of cells and not from rare,
of diverse lineages genetically distinct subclones that may have been present in
Transduced cells clonally expanded from in vitro cultures de- the original culture.
scribed above were assessed for their leukemogenic potential The different lineage derivations of the leukemias were fur-
in sub-lethally irradiated, syngeneic C57BL/6 mice. Within a ther confirmed by immunoglobulin (Ig) gene rearrangement sta-
relatively short latency period (mean 3 months) similar to that tus. AML cells maintained germline configurations for IgH genes
observed above for in vivo experiments, all animals succumbed whereas ALL cells displayed IgH gene rearrangements in the
to acute leukemias that expressed the MLL fusion protein (Fig- absence of light chain gene rearrangements (Figure 3C and data
not shown), suggesting an arrest at a late pro-B (fraction C)ures 3A and 3B). The leukemias exhibited diverse pathologic
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Figure 3. Progenitors transformed by MLL-GAS7 induce leukemias of different lineage with short latency
A: Survival curves are shown for cohorts (n  10) of mice injected with cells transformed by different MLL fusion proteins (So and Cleary, 2002, 2003) or
mock injected controls (control). MLL-GAS7 results in leukemias with shorter latencies than MLL-AFX or MLL-FKHRL1.
B: Detection of MLL-GAS7 fusion protein in the blasts of leukemic mice. Western blot analysis shows MLL-GAS7 and wt MLL in leukemia cells. By comparison,
Ba/F3 pro-B cells contain only wild-type MLL.
C: Phenotypic and clonal analysis of leukemic blasts from MLL-GAS7 mice. Upper panels show typical FACS profiles of leukemic cells from mice with AML,
ABL, and ALL, respectively. Shadow profiles represent FACS staining obtained with antibodies specific for the indicated cell surface antigens. Gray lines
represent staining obtained with isotype control antibodies. Lower panels show the results of Southern blot analysis for immunoglobulin gene (IG-JH4) and
MSCV proviral integration status of leukemic cells. gl, germline configuration of IG-JH4 gene.
stage of differentiation (Hardy et al., 1991). ABL cells displayed versely, mice with ALL had extensive involvement of lymph
nodes and thymus, but only moderate liver and spleen infiltrates.germline configurations for the IgH gene, consistent with matu-
ration arrest at a stage prior to initiation of the rearrangement Mice with ABL typically displayed composite features with
lymph node as well as liver and spleen enlargement. AML wasprocess.
The leukemia subtypes were also characterized by distinc- associated with very high peripheral blood cell counts and circu-
lating blasts, while ABL and ALL displayed modestly elevatedtive pathologic presentations (Figure 4 and Table 1). Mice with
AML displayed massive leukemic infiltration in the liver and blood cell counts and fewer blasts (Table 1). Taken together,
these studies indicated that cells transformed in vitro by MLL-spleen, but no involvement of other lymphoid organs. Con-
Table 1. Features of leukemic mice injected with MLL-GAS7 transformed cells
Normal AML ABL ALL
Mice with disease (N  15) n.a. 8 4 3
Disease latency (days)a n.a. 115  37 100  42 90  35
WBC (103/l)a 6.9  1.2 100  84 15  3 19  4
Blasts in peripheral blood (%)a 0 56  7 24  6 26  12
Liver weight (mg)a 0.45  0.12 4.3  3.2 2.2  0.3 1.5  0.5
Spleen weight (mg)a 0.12  0.03 0.8  0.5 0.7  0.3 0.4  0.3
Mice with lymphoid organ involvement (%) n.a. 0 75 100
a Values shown as mean  standard deviation.
n.a., not applicable.
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Figure 4. Pathologic features of leukemias in-
duced by MLL-GAS7-transduced MPP-like cells
A: Left panel shows comparative spleen sizes in
mice with AML (or ABL) and ALL versus normal.
Right panels show the anatomic distribution of
organ involvement in mice with AML and ABL
(or ALL), respectively. Arrows and arrowheads
indicate infiltrated liver/spleen and enlarged
lymphoid nodes, respectively.
B: Histologic features of liver, spleen, and periph-
eral blood from mice with AML, ABL, and ALL,
respectively. Periportal areas of liver show exten-
sive leukemic infiltration in AML and ABL. Spleens
show varying degrees of effacement of normal
architecture, AML and ABL to a greater extent
than ALL. Magnifications: liver and spleen, 200;
blood, 400.
GAS7 with MPP-like features were capable of inducing three tirely different set of genes including GATA-2, GATA-3, and
SCL, but were notable for their lack of expression of the abovedifferent leukemias in vivo.
myeloid genes. Interestingly, ABL cells expressed genes com-
mon to both myeloid and lymphoid progenitors. While the con-AML, ALL, and ABL display distinct
trasting expression profiles exhibited by AML and ALL reflectedgene expression profiles
their lineage-specific origins, co-expression of both lymphoidHematopoietic lineage commitment is regulated in part by the
and myeloid genes in ABL suggested maturation arrest at a morefunctional balance of transcription factors, which turn on/off
specific lineage-defining genes. Thus, it was of interest to assess uncommitted stage of differentiation consistent with myeloid/
lymphoid bipotential progenitors. The expression profile inthe definitive gene expression profiles of the various leukemias
in comparison with transduced MPP-like cells. RT-PCR analysis MPP-like cells was even broader than that of ABL, consistent
with a model in which the most primitive progenitors expressshowed that AML cells expressed myeloid-specific genes in-
cluding myeloperoxidase (MPO), G-CSF-R, M-CSF-R, and GM- the widest array of genes, many of which are silenced during
subsequent lineage commitment (Hu et al., 1997; Enver andCSF-R, but not genes normally expressed in early lymphoid
progenitors (Figure 5). Conversely, ALL cells expressed an en- Greaves, 1998).
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Figure 5. AML, ALL, and ABL cells exhibit distinct gene expression profiles
Results of RT-PCR analyses are shown for expression of transcripts from the
genes indicated to the left of the respective panels. Total RNA was isolated
from short-term (7 day) explants of leukemic BM cells of different leukemia
types (listed at the tops of lanes) or cultured MPP-like cells. RNA isolated
from unfractionated bone marrow cells (WBM) served as a positive control.
Identification of a leukemogenic, biphenotypic
progenitor transformed by MLL-GAS7
Biphenotypic (B220/Mac-1) progenitors were also transiently
generated in vitro from MPP-like cells. When cultured under
myeloid conditions (RPMI containing 20% FCS and 20% WEHI- Figure 6. Biphenotypic progenitors transformed by MLL-GAS7 induce my-
eloid and lymphoid leukemiasconditioned medium as a source of IL-3), MPP-like cells pro-
A: Sca/kit-positive MPP-like cells transformed by MLL-GAS7 spontaneouslygressively changed their phenotype by first downregulating
differentiated into biphenotypic and myeloid progenitors during long-termSca-1, then upregulating B220 and Mac-1, and finally downreg-
in vitro culture. FACS profiles are shown for cells removed from in vitro cultures
ulating B220 (Figure 6A). These results suggested that Sca-1/ at the indicated time points (shown at top of profiles). MPP-like, progenitors
with MPP features; B/M, biphenotypic progenitors; M, myeloid precursors.c-kit MPP-like cells could directly give rise to B220/Mac-1/
Black square indicates biphenotypic progenitors (B220/Mac-1) purifiedc-kit biphenotypic cells, which further differentiated into my-
by FACS for injection into syngeneic mice in Figure 6B.
eloid precursors (Mac-1/c-kit). Since the in vitro culture condi- B: Biphenotypic progenitors induce both myeloid and lymphoid leukemias.
FACS profiles show the surface marker expression of typical AML or ALLtions favored myeloid differentiation, the differentiation potential
that arose following injection of FACS-purified biphenotypic (B220/Mac1)of biphenotypic cells was also examined in vivo. B220/Mac-1
progenitors transformed in vitro by MLL-GAS7. Lower panels show the immu-
cells were purified by two rounds of FACS (Figure 6A) and noglobulin gene (IG-JH4) and MSCV proviral integration status of represen-
tative AML and ALL cells, respectively, as detected by Southern blot analysis.then injected (105/mouse) into sub-lethally irradiated, syngeneic
gl, germline configuration of IG-JH4 gene.recipient mice. Acute leukemias developed in 4 of 10 trans-
planted mice after a latency period of approximately 7 months.
Immunophenotype and genotype analyses revealed that half
the mice had AML and half had ALL (Figure 6B). All leukemias
displayed configurations of proviral integration sites that were Multilineage transformation arises from multipotential
identical to the injected biphenotypic cells as well as the parental progenitors but not committed myeloid
MPP-like cells, indicating that they were derived from a single or lymphoid progenitors
clone of transduced cells. These studies suggested that trans- To identify normal progenitors susceptible to MLL-induced
formed MPP-like cells were capable of sequentially differentiat- multilineage oncogenic readouts, in vitro transformation assays
ing into biphenotypic progenitors with the capacity to further were performed using purified populations of known phenotypi-
differentiate along either the myeloid or lymphoid lineages to cally defined progenitor cells. HSC, common lymphoid progeni-
tors (CLP), common myeloid progenitors (CMP), granulocyte/induce AML or ALL, respectively.
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preceding section above, while transformed CMP and GMPTable 2. Transformation of highly purified stem/progenitor cells by MLL-GAS7
did not. Conversely, under lymphoid culture conditions, onlyPhenotype of cells growing in vitro
transduced HSC resulted in the growth of third round colonies
Transduced population Myeloid conditions Lymphoid conditions (Figure 7). These colonies were heterogenous in appearance,
varying from densely compact to diffuse, and were composed ofHSC Myeloida Multilineage
CLP n.a. Lymphoidb at least three phenotypically distinct subpopulations: (1) Mac-1
CMP Myeloid n.a. cells with features of myeloid precursors; (2) B220/CD19 cells
GMP Myeloid n.a.
with features of B-lymphoid precursors; and (3) B220/Mac-1MEP n.a. n.a.
cells with features of biphenotypic progenitors (Figure 7). Al-
a HSC gave a small fraction of B220/Mac-1 positive biphenotypic progenitors though transduced CLP gave lymphoid colonies in the second
in myeloid conditions.
plating (Figure 7), they failed to replate (Table 2). These resultsb CLP gave only transient readout in the second round of serial plating.
indicate that committed myeloid or lymphoid progenitors aren.a., not applicable due to lack of progenitor colony formation under in
vitro conditions at second or third rounds of serial plating. not the targets for multilineage readouts induced by MLL-GAS7,
and only transduced HSC that are capable of differentiating into
MPP can give rise to transformed biphenotypic progenitors.
Discussionmonocyte progenitors (GMP), and megakaryocyte/erythocyte
progenitors (MEP) were isolated by FACS based on their surface
In the present study, we demonstrate the induction of mixedphenotypes (Kondo et al., 1997; Akashi et al., 2000). Purified
lineage leukemias by an MLL oncogene. These leukemias ap-cells were transduced with retroviruses and subjected to serial
peared to result from a primary effect of MLL-GAS7 to impair thereplating analysis in methylcellulose medium containing cyto-
differentiation of cells with features of multipotent hematopoietickine cocktails that favored myeloid or lymphoid differentiation
progenitors. MLL-GAS7 enhanced the in vitro clonogenic prop-(Figure 1A). Under myeloid culture conditions, transduced HSC,
erties of Sca-1/c-kit/lin/lo cells under conditions where pro-CMP, and GMP generated colonies through the third round of
genitors normally exhaust their growth potential and undergoserial plating (Table 2). The transformed cells had phenotypic
terminal differentiation. Previous studies have shown that thefeatures of myeloid precursors (c-kit/Gr-1/Mac-1) corre-
highly purified population co-expressing these antigens insponding to maturation arrest at a late stage of myeloid differen-
mouse bone marrow is comprised of three functionally relatedtiation, most probably positioned developmentally downstream
hematopoietic progenitor sets with different self-renewal poten-of GMP but prior to terminal differentiation as observed for
tials: long-term self-renewing HSCs (lin/lo/thy1.1lo/Flk2/c-kithi/another MLL oncoprotein (A. Cozzio et al., submitted). HSC
yielded a minor fraction of Mac-1/B220 biphenotypic cells Sca-1hi); short-term self-renewing HSCs (lin/lo/thy1.1lo/Flk2/
c-kithi/Sca-1hi); and MPP (lin/lo/thy1.1-/Flk2/c-kithi/Sca-1hi/(Table 2 and data not shown) similar to those described in the
Figure 7. Multilineage transformation arises from
HSC but not committed progenitors
FACS profiles show the phenotypic features of
cells growing in methylcellulose cultures at the
end of the third round of serial replating (except
CLP, which are shown at the second round).
Arrows indicate the morphology of specific cell
populations that were FACS-purified based on
their surface marker expression and stained with
Wright-Giemsa (magnification 800). The puri-
fied stem/progenitor populations that were
transduced with MLL-GAS7 to initiate the cultures
are indicated on the left. Culture conditions (indi-
cated to the right) were optimized by specific
cytokine cocktails, for growth of lymphoid (IL-7,
SCF, Flt-3L) or myeloid (IL-3, IL-6, GM-CSF, SCF)
progenitors.
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Mac1lo) without detectable self-renewal potential (Morrison and
Weissman, 1994; Morrison et al., 1997; Christensen and Weiss-
man, 2001). These represent the most primitive populations of
defined progenitors with potential to differentiate into all known
hematopoietic cell lineages (Morrison et al., 1997). The progeni-
tors affected by MLL-GAS7 in vitro are most comparable (but
not identical) phenotypically to MPP, the direct progeny of short-
term HSC. The multilineage differentiation potentials of the
transformed cells were suggested by their transcriptional pro-
grams and confirmed by an ability to induce leukemias of three
different lineages in mice. MLL-GAS7 also induced multilineage
readouts from purified HSC in vitro, indicating that both HSC
and MPP are potential targets for the induction of mixed lineage
leukemias by MLL oncogenes.
MLL-GAS7 appears particularly potent at altering the growth
properties of MPP-like cells compared to other MLL fusion pro-
teins by mechanisms that remain undefined. We have observed
that MLL-ENL is also capable of inducing the outgrowth of
biphenotypic progeny from purified HSC under in vitro lymphoid
culture conditions, but it is significantly less effective than MLL-
GAS7 (data not shown). Recently, MLL-ENL was reported to
transform chicken cells with phenotypic features of MPP
(Schulte et al., 2002). Their differentiation potential, however,
was restricted to the myeloid lineage and they failed to induce
lymphoid leukemias, further suggesting that MLL-ENL strongly
favors myeloid transformation in vivo consistent with our recent
observations using purified progenitor subsets (A. Cozzio et al.,
submitted). Thus, despite the targeting of MLL oncogenes to
multipotent progenitors, specific fusion partners appear to heav-
ily influence the actual features of MLL-associated leukemias
presumably through interactions with lineage-specific factors.
Although the in vitro growth and differentiation properties
of MPP/HSC are perturbed by MLL oncogenes, the resultant Figure 8. Proposed model depicts cellular transformation scheme by MLL
leukemias typically display features of maturation arrest at a later fusion genes in murine leukemias
stage of differentiation. This suggests that although multipotent The lineal relationships are shown for phenotypically defined hematopoietic
progenitors and stem cells based on Reya et al. (2001). Transduction ofhematopoietic progenitors are impaired in their differentiation
MLL-GAS7 impairs the in vitro differentiation of multipotent HSC or MPP.potential, they retain an ability to generate more differentiated
Transduced HSC/MPP give rise to novel biphenotypic (B220/Mac1) pro-progeny. This hypothesis is consistent with the finding that
genitors in vitro and leukemias with features of AML, ALL, or ABL in vivo.
forced expression of MLL-ENL in purified HSC yielded acute Leukemias are comprised of myeloid (AML) or lymphoid (ALL) precursors,
myeloid and not stem cell leukemias (A. Cozzio et al., submitted). or progenitors expressing both myeloid and lymphoid antigens and genes
(ABL).Similarly, stem cell leukemia is not a feature of AML1-ETO posi-
tive patients in spite of expression of the fusion gene in the
HSC compartments (Miyamoto et al., 2000). Taken together,
these studies suggest a model in which MLL fusion genes might
progenitors (Akashi et al., 2000). Conversely, biphenotypic ABLenhance the self-renewal potential of multipotent progenitors
cells and MPP-like cells expressed a broader range of genesthat otherwise retain an ability to differentiate into downstream
common to both the myeloid and lymphoid lineages. Theseprogeny. The latter may be more susceptible to the differentia-
observations are consistent with the proposed multilineagetion blocking effects of MLL oncoproteins or more prone to
priming feature of uncommitted progenitors, which expressdevelop the secondary mutations required for complete leuke-
transcripts for most of the known key transcription factors,mogenic transformation (Figure 8).
growth factor receptors, and other genes encoding lineage-Consistent with the above model, transduced Sca-1/c-kit
exclusive functions (Hu et al., 1997; Enver and Greaves, 1998).progenitors gave rise to biphenotypic progeny in vitro and, when
Under this model of hematopoietic differentiation, unilineagetransplanted, to biphenotypic leukemias (ABL) in vivo (in addi-
commitment is achieved by specific upregulation of genes fortion to AML and ALL). Gene expression profiling studies of the
one particular lineage and downregulation of genes for all otherleukemic cells were consistent with immunophenotype and Ig
lineages. We hypothesize that activating mutations of MLL,genotype analyses on defining three distinct lineage derivations
which is genetically implicated in maintaining normal develop-of the leukemias. Genes required for myeloid development, such
mental gene expression, may oppose unilineage differentiationas GM-CSF-R, M-CSF-R, and G-CSF-R (Zhu and Emerson,
by preventing the downregulation of genes involved in main-2002), were expressed by AML but not ALL cells. The latter
taining the multipotentiality of HSC/MPP. Our limited transcrip-expressed a different non-overlapping set of genes including
GATA3, which is expressed by normal CLP but not myeloid tional profiling studies are also consistent with recent studies of
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CD34/CD16/32lo). The properties of purified stem/progenitor cells werehuman leukemias harboring MLL chromosomal translocations,
verified by in vitro cell culture assays and/or in vivo studies to establishwhich display a gene expression profile distinct from ALL and
appropriate lineage development.AML, respectively (Armstrong et al., 2002; Yeoh et al., 2002).
Purified hematopietic cells were transduced by spinoculation with viral
Taken together, these results suggest that we have successfully supernatants collected 3 days after transfection of phoenix cells. For in vivo
modeled the distinctive biphenotypic human leukemias com- assays, 105 transduced Ly5.2 cells were transplanted together with 2  105
Ly5.1 total bone marrow cells into the retro-orbital venous sinus of 6-week-monly associated with MLL mutations.
old syngeneic, lethally irradiated [10.5 Gy total body 	 irradiation (135Cs)]The lymphoid and myeloid lineages diverge at the level of
Ly5.1 C57BL/6 mice. For in vitro assays, transduced cells were plated invery early progenitors (e.g., CLP versus CMP), but considerable
1% methylcellulose (StemCell Technologies, Vancouver, BC, Canada) sup-
evidence indicates a close developmental relationship between plemented with either myeloid or lymphoid cytokines in the presence or
B-lymphoid and myeloid cells in normal definitive hematopoiesis absence of 1 mg/ml G418. Myeloid conditioned methylcellulose contained an
(Borrello et al., 2001 for review). Although CMP and CLP have Iscove’s Modified Dulbecco’s Medium (IMDM)-based Methocult (Methocult
M3231; StemCell Technologies) supplemented with 20 ng/ml stem cell factorbeen shown to exhibit limited lineage plasticity in giving rise to
(SCF) and 10 ng/ml each of IL-3, IL-6, and GM-CSF (R&D Systems, Minneap-lymphoid and myeloid progeny, respectively (Kondo et al., 1997,
olis, Minnesota). Lymphoid conditioned methylcellulose consisted of IMDM-2000; Akashi et al., 2000; Traver et al., 2000), they did not
based Methocult M3630 (StemCell Technologies) containing 10 ng/ml hu-
yield bi-lineage oncogenic readouts in response to MLL-GAS7. man IL-7 supplemented with 20 ng/ml each of SCF and Flt-3 ligand. After 7
Rather, transduction of CMP (and GMP) resulted exclusively in days culture, colonies were counted to calculate the transduction efficiency.
Single-cell suspensions (104 cells) of G418-resistant colonies were thentransformed myeloid progeny, further confirming the ability of
replated in methylcellulose medium supplemented with growth factors with-MLL fusion proteins to induce myeloid leukemias from commit-
out G418. Plating was repeated every 7 days. In each round of replating,ted progenitors (A. Cozzio et al., submitted). Bipotential progeni-
single cell suspensions were also expanded in RPMI liquid medium con-
tors that give rise to both B cells and macrophages at higher taining 20% FCS plus 20% WEHI-conditioned medium. For tumorigenicity
frequencies were first identified in murine fetal liver (Cumano et assays, 105 or 106 immortalized cells were injected into the retro-orbital
al., 1992). The existence of similar bipotential progenitors in venous sinus of 6-week-old syngeneic Ly5.2 C57BL/6 mice, which had
received a sublethal dose (5.25 Gy) of total body 	 irradiation (135Cs). Miceadult hematopoeisis has recently been confirmed by isolation
were maintained on antibiotic water to avoid infection and monitored forof a common B/macrophage precursor (c-kit/CD45R/CD19)
development of leukemia by complete blood count, blood smear, and FACSin postnatal bone marrow (Montecino-Rodriguez et al., 2001).
analysis. Tissues were fixed in buffered formalin, sectioned, and stained
While it is difficult to make a direct comparison between the with hematoxylin and eosin (H&E) for histological analysis.
common B/macrophage precursor identified in normal bone
marrow with the biphenotypic ABL cells in our studies, the Cell sorting and immunophenotypic analysis by FACS
Immunophenotypic analysis was performed by FACS using fluorochrome-immunophenotypes (c-kit/CD19) and Ig genotypes (absence
conjugated monoclonal antibodies to Sca-1 (D7 clone), c-kit (2B8 clone),of DJH and VDJH rearrangements) of ABL cells suggest that
CD43 (S7 clone), Mac-1 (M1/70 clone), Gr-1 (RB6-8C5 clone), CD19 (1D3they originate from more immature progenitors than the known
clone), B220 (RA3-6B2 clone), CD3
 (145-2C11), CD4 (RM 4-5), CD8a (53-
B/macrophage precursors. Nevertheless, identification of B220/ 6.7), Thy1.2 (53-2.1), and Ter-119 (TER-119) (Pharmingen Inc, San Diego,
Mac-1 biphenotypic cells that induced both acute lymphoid California), respectively. Staining was generally performed on ice for 15–30
min. Cells were washed twice in staining medium and resuspended in 1 g/and myeloid leukemias is most consistent with a “lineage pro-
ml propidium iodine (PI) before analysis using a Moflops (modified triplemiscuity” model and strongly suggests that leukemogenic trans-
laser Cytomation/Becton Dickinson hybrid FACS) or a Vantage (modifiedformation of bipotential or multipotential progenitors by MLL
triple laser [488 nm argon laser, 599 nm dye laser, and UV laser] [Bectonmutations leads to multilineage leukemias.
Dickinson Immunocytometry System, Mountain View, California]). Dead cells
were gated out by high PI staining and forward light scatter. For sorting
Experimental procedures HSC, CLP, CMP, GMP, and MEP, bone marrow cells from 4- to 8-week-
old mice were stained with specific conjugated and unconjugated antibodies
DNA constructs as previously described (Morrison and Weissman, 1994; Kondo et al., 1997;
A full-length GAS7 cDNA was amplified by RT-PCR using primers based on Morrison et al., 1997; Akashi et al., 2000) and double-sorted using the FACS
the published sequence (accession number AB007854) (Megonigal et al., Vantage.
2000). The resulting GAS7 cDNA was inserted into the NruI and XhoI sites
of MSCV-neo-MLL5 (DiMartino et al., 2002) in-frame with MLL amino acids Genotype analyses
1–3696 to yield an MSCV/MLL-GAS7 fusion construct, which was se- Genomic configurations of Ig genes and retroviral integrations were deter-
quenced to exclude mutations introduced by PCR. mined by Southern blot analyses. Genomic DNAs were extracted from tumor
tissues/cells and digested with appropriate restriction enzymes (XbaI for Ig
In vitro and in vivo transformation assays gene rearrangement; BamHI or BamHI/ScaI for viral integration studies).
In vitro hematopoietic progenitor transformation assays were performed as MSCV/MLL-GAS7 contains one internal BamHI site and no ScaI sites. Di-
previously described (So and Cleary, 2002, 2003) except for differences in gested DNAs were separated in 0.8% agarose, transferred to nylon mem-
the preparation of enriched/purified hematopoietic stem/progenitors cells. branes, and hybridized with radiolabeled DNA probes. JH4- and J-specific
Partial or highly purified hematopoietic cells were prepared from the bone probes were used for Ig heavy and light chain gene assessment, respectively.
marrow of 4- to 10-week-old Ly5.2 C57BL/6 mice by (1) pretreatment with For MSCV/MLL-GAS7 retroviral integration studies, a human MLL cDNA
5-fluorouracil (5-FU) (100 mg/kg) 5 days before bone marrow harvesting; (2) probe (Tkachuk et al., 1992) spanning nucleotides 3295–3726 (accession
positive selection for c-kit expression by magnetic activated cell sorting number NM_005933) was employed.
(MACS); or (3) fluorescent activated cell sorting (FACS) using specific anti-
bodies to defined cell surface markers for various hematopoietic stem and Western blot and RT-PCR analyses
progenitor cells as previously described (Morrison and Weissman, 1994; Lysate proteins (30 g) were fractionated in 5% polyacylamide gel and
Kondo et al., 1997; Morrison et al., 1997; Akashi et al., 2000). Phenotypic transferred to ECL membranes (Amersham Pharmacia Biotech) using Tris-
populations were defined as HSC (Lin/lo/Thy1.1lo/c-kithi/Sca-1hi), CLP (Lin/ glycine-SDS transfer buffer. After blocking, membranes were probed with
c-kitlo/Sca-1lo/IL-7Rlo/Thy1.1), CMP (c-kithi/Sca-1/CD34/CD16/32lo), GMP monoclonal antibody N4.4 directed against an MLL amino-terminal epitope
as previously described (So and Cleary, 2002, 2003). Total RNAs purified(Lin/c-kithi/Sca-1/CD34/CD16/32hi), and MEP (Lin/c-kithi/Sca-1/
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C.M., and Canaani, E. (1992). The t(4;11) chromosome translocation of hu-from bone marrow cultures using Trizol (Life Technologies) were amplified
man acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax,by RT-PCR using gene-specific primers as previously described (Akashi et
to the AF-4 gene. Cell 71, 701–708.al., 2000; Kondo et al., 2000). The details of primer sequences and PCR
conditions are available by request. Hardy, R.R., Carmack, C.E., Shinton, S.A., Kemp, J.D., and Hayakawa, K.
(1991). Resolution and characterization of pro-B and pre-pro-B cell stages
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